NO20024908L - 8<beta>-hydrokarbyl-substituerte östratriener for anvendelse som selektive östrogener - Google Patents

8<beta>-hydrokarbyl-substituerte östratriener for anvendelse som selektive östrogener

Info

Publication number: NO20024908L
Authority: NO; Norway
Prior art keywords: sup; compounds; substituted; estrogens; action
Prior art date: 2000-04-12

Application number

NO20024908A

Other languages

English (en)

Other versions

NO325337B1 (no

NO20024908D0 (no

Inventor

Olaf Peters

Alexander Hillisch

Ina Thieme

Walter Elger

Christa Hegele-Hartung

Uwe Kollenkirchen

Karl-Heinrich Fritzemeier

Vladimir Patchev

Original Assignee

Schering Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-12

Filing date

2002-10-11

Publication date

2002-11-13

2000-04-12 Priority claimed from DE10019167A external-priority patent/DE10019167A1/de

2002-10-11 Application filed by Schering Ag filed Critical Schering Ag

2002-10-11 Publication of NO20024908D0 publication Critical patent/NO20024908D0/no

2002-11-13 Publication of NO20024908L publication Critical patent/NO20024908L/no

2008-03-31 Publication of NO325337B1 publication Critical patent/NO325337B1/no

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0062—Estrane derivatives substituted in position 17 alfa not substituted in position 17 beta
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0074—Esters
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Gynecology & Obstetrics (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Hematology (AREA)
Pregnancy & Childbirth (AREA)
Pulmonology (AREA)
Toxicology (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20024908A 2000-04-12 2002-10-11 8<beta>-hydrokarbyl-substituerte ostratriener og anvendelse derav for fremstilling av legemidler NO325337B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE10019167A DE10019167A1 (de)	2000-04-12	2000-04-12	Substituierte Estratriene als selektiv wirksame Estrogene
US20737000P	2000-05-26	2000-05-26
PCT/EP2001/004290 WO2001077139A1 (de)	2000-04-12	2001-04-12	8.beta.-hydrocarbyl-substituierte estratriene als selektiv wirksame estrogene

Publications (3)

Publication Number	Publication Date
NO20024908D0 NO20024908D0 (no)	2002-10-11
NO20024908L true NO20024908L (no)	2002-11-13
NO325337B1 NO325337B1 (no)	2008-03-31

Family

ID=26005365

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20024908A NO325337B1 (no)	2000-04-12	2002-10-11	8<beta>-hydrokarbyl-substituerte ostratriener og anvendelse derav for fremstilling av legemidler
NO20024907A NO20024907L (no)	2000-04-12	2002-10-11	8<beta>-substituerte-11<beta>-pentyl- og 11<beta>-heksyl- östra-1,3,5(10)-trienderivater

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20024907A NO20024907L (no)	2000-04-12	2002-10-11	8<beta>-substituerte-11<beta>-pentyl- og 11<beta>-heksyl- östra-1,3,5(10)-trienderivater

Country Status (26)

Country	Link
US (3)	US20040029847A1 (no)
EP (2)	EP1272504B1 (no)
JP (2)	JP3828423B2 (no)
CN (1)	CN100453549C (no)
AT (2)	ATE302790T1 (no)
AU (3)	AU5834101A (no)
BG (1)	BG107173A (no)
BR (1)	BR0109983A (no)
CA (1)	CA2406177C (no)
CZ (1)	CZ20023382A3 (no)
DE (1)	DE50112561D1 (no)
DK (2)	DK1272505T3 (no)
EA (1)	EA006299B1 (no)
EE (1)	EE200200589A (no)
ES (2)	ES2287127T3 (no)
HK (1)	HK1057219A1 (no)
HR (1)	HRP20020892B1 (no)
HU (1)	HUP0300335A2 (no)
IL (2)	IL152248A0 (no)
MX (1)	MXPA02010066A (no)
NO (2)	NO325337B1 (no)
NZ (1)	NZ543724A (no)
PL (1)	PL207488B1 (no)
PT (1)	PT1272504E (no)
SK (1)	SK14632002A3 (no)
WO (2)	WO2001077139A1 (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MXPA02010066A (es) *	2000-04-12	2003-06-04	Schering Ag	Estratrienos sustituidos en 8beta-hidrocarbilo para uso como estrogenos selectivos.
DE10027887A1 (de)	2000-05-31	2001-12-13	Jenapharm Gmbh	Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE10039199A1 (de) *	2000-08-10	2002-02-21	Schering Ag	Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen
GB0020498D0 (en) *	2000-08-18	2000-10-11	Sterix Ltd	Compound
DE10151363A1 (de) *	2001-10-17	2003-05-08	Schering Ag	Somatotrope Therapie
DE10226326A1 (de) *	2002-06-11	2004-01-15	Schering Ag	9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene
ATE410170T1 (de) *	2003-03-27	2008-10-15	Pantarhei Bioscience Bv	Verwendung von estrogenen zur behandlung von männerunfruchtbarkeit
DE10318896A1 (de)	2003-04-22	2004-11-25	Schering Ag	8beta-Vinyl-11beta-(omega-substituierte)alkyl-estra-1,3,5(10)-triene
DE602004014020D1 (de) *	2003-11-26	2008-07-03	Bayer Schering Pharma Ag	Prävention und behandlung von hypertonen herzerkrankungen mit den selektiven östrogenen 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol und 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol
US7534780B2 (en)	2004-05-21	2009-05-19	Bayer Schering Pharma Aktiengesellschaft	Estradiol prodrugs
DE102005057225A1 (de) *	2005-11-29	2007-05-31	Bayer Schering Pharma Ag	Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE102005057224A1 (de) *	2005-11-29	2007-05-31	Bayer Schering Pharma Ag	Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EP2014672A1 (en) *	2007-07-12	2009-01-14	Bayer Schering Pharma Aktiengesellschaft	8-beta-substituted estratrienes as selectively active estrogens
WO2009100871A2 (en) *	2008-02-13	2009-08-20	Bayer Schering Pharma Aktiengesellschaft	Drug delivery system with stabilising effect
CN101945646A (zh) *	2008-02-13	2011-01-12	拜耳先灵医药股份有限公司	含*的药物递送*
EP2143432A1 (en)	2008-07-11	2010-01-13	Bayer Schering Pharma AG	9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer
CN102215818A (zh) *	2008-11-21	2011-10-12	拜耳先灵医药股份有限公司	药物递送***
CA2856520C (en)	2011-11-23	2021-04-06	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US9301920B2 (en)	2012-06-18	2016-04-05	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US20150196640A1 (en)	2012-06-18	2015-07-16	Therapeuticsmd, Inc.	Progesterone formulations having a desirable pk profile
US10806697B2 (en)	2012-12-21	2020-10-20	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en)	2012-06-18	2020-10-20	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US20130338122A1 (en)	2012-06-18	2013-12-19	Therapeuticsmd, Inc.	Transdermal hormone replacement therapies
US10471072B2 (en)	2012-12-21	2019-11-12	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en)	2012-12-21	2020-02-25	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en)	2012-12-21	2020-01-21	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en)	2012-12-21	2015-11-10	Therapeuticsmd, Inc.	Soluble estradiol capsule for vaginal insertion
US11266661B2 (en)	2012-12-21	2022-03-08	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en)	2012-12-21	2022-02-15	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
AU2015264003A1 (en)	2014-05-22	2016-11-17	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
WO2017173044A1 (en)	2016-04-01	2017-10-05	Therapeuticsmd Inc.	Steroid hormone compositions in medium chain oils
CA3020153A1 (en)	2016-04-01	2017-10-05	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical composition
US11633405B2 (en)	2020-02-07	2023-04-25	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2743E (fr) *	1902-01-11	1904-12-15	Adolphe Ernest Pointe	Panification augmentant le rendement et la digestibilité
JPS454059Y1 (no) *	1967-11-04	1970-02-25
JPS454060Y1 (no) *	1967-12-11	1970-02-25
US3501530A (en) *	1968-02-27	1970-03-17	American Cyanamid Co	Substituted naphthalenones,naphthalenediones and d-homo - beta - nor estra-1,3,5(10),9(11)-tetraenes
US3681407A (en) *	1969-06-18	1972-08-01	American Cyanamid Co	3-methoxy 8{62 -methylestra 1,3,5(10),9(11)-tetraene-17{62 -carboxylic acid lower alkyl ester and intermediates in the preparation thereof
US3806546A (en) *	1969-06-18	1974-04-23	American Cyanamid Co	Steroid-like compounds and method of synthesis
US3709878A (en) *	1970-07-20	1973-01-09	Sandoz Ag	8 alpha-methyl-substituted-steroids
US3736345A (en) *	1971-05-18	1973-05-29	American Cyanamid Co	Steroid-like compounds and method of synthesis
US4961931A (en) *	1982-07-29	1990-10-09	Alza Corporation	Method for the management of hyperplasia
DE4018828C2 (de) *	1989-06-08	1999-05-12	Schering Ag	Verfahren zur Herstellung C7-alpha-substituierter 8alpha- und 8ß-Estra-1,3,5(10)-triene und C8-alpha-substituierter Estra-1,3,5(10)-triene sowie neue Zwischenprodukte für dieses Verfahren
US6861415B2 (en) *	1996-05-01	2005-03-01	The United States Of America As Represented By The Department Of Health And Human Services	21-substituted progesterone derivatives as new antiprogestational agents
EP1131336B1 (en) *	1998-11-20	2002-08-28	Akzo Nobel N.V.	Estrogenic estra-1,3,5(10)-trienes with differential effects on the alpha and beta estrogen receptors, having a linear hydrocarbon chain of from 5-9 carbon atoms in position 11
MXPA02010066A (es) *	2000-04-12	2003-06-04	Schering Ag	Estratrienos sustituidos en 8beta-hidrocarbilo para uso como estrogenos selectivos.
DE10019167A1 (de) *	2000-04-12	2001-10-18	Schering Ag	Substituierte Estratriene als selektiv wirksame Estrogene
DE10318896A1 (de) *	2003-04-22	2004-11-25	Schering Ag	8beta-Vinyl-11beta-(omega-substituierte)alkyl-estra-1,3,5(10)-triene

2001
- 2001-04-12 MX MXPA02010066A patent/MXPA02010066A/es active IP Right Grant
- 2001-04-12 JP JP2001575608A patent/JP3828423B2/ja not_active Expired - Lifetime
- 2001-04-12 CZ CZ20023382A patent/CZ20023382A3/cs unknown
- 2001-04-12 NZ NZ543724A patent/NZ543724A/en unknown
- 2001-04-12 IL IL15224801A patent/IL152248A0/xx active IP Right Grant
- 2001-04-12 EA EA200201052A patent/EA006299B1/ru not_active IP Right Cessation
- 2001-04-12 PL PL358667A patent/PL207488B1/pl not_active IP Right Cessation
- 2001-04-12 ES ES01931609T patent/ES2287127T3/es not_active Expired - Lifetime
- 2001-04-12 WO PCT/EP2001/004290 patent/WO2001077139A1/de active IP Right Grant
- 2001-04-12 ES ES01940331T patent/ES2245694T3/es not_active Expired - Lifetime
- 2001-04-12 US US10/257,287 patent/US20040029847A1/en not_active Abandoned
- 2001-04-12 AU AU5834101A patent/AU5834101A/xx active Pending
- 2001-04-12 DK DK01940331T patent/DK1272505T3/da active
- 2001-04-12 AU AU2001273945A patent/AU2001273945A1/en not_active Abandoned
- 2001-04-12 CN CNB018107745A patent/CN100453549C/zh not_active Expired - Fee Related
- 2001-04-12 AT AT01940331T patent/ATE302790T1/de not_active IP Right Cessation
- 2001-04-12 EP EP01931609A patent/EP1272504B1/de not_active Expired - Lifetime
- 2001-04-12 EE EEP200200589A patent/EE200200589A/xx unknown
- 2001-04-12 EP EP01940331A patent/EP1272505B1/de not_active Expired - Lifetime
- 2001-04-12 BR BR0109983-3A patent/BR0109983A/pt not_active IP Right Cessation
- 2001-04-12 SK SK1463-2002A patent/SK14632002A3/sk unknown
- 2001-04-12 WO PCT/EP2001/004289 patent/WO2001077138A1/de active IP Right Grant
- 2001-04-12 AT AT01931609T patent/ATE363487T1/de active
- 2001-04-12 US US10/257,288 patent/US7378404B2/en not_active Expired - Fee Related
- 2001-04-12 PT PT01931609T patent/PT1272504E/pt unknown
- 2001-04-12 HU HU0300335A patent/HUP0300335A2/hu unknown
- 2001-04-12 DE DE50112561T patent/DE50112561D1/de not_active Expired - Lifetime
- 2001-04-12 DK DK01931609T patent/DK1272504T3/da active
- 2001-04-12 AU AU2001258341A patent/AU2001258341B2/en not_active Ceased
- 2001-04-12 CA CA2406177A patent/CA2406177C/en not_active Expired - Fee Related
2002
- 2002-10-08 BG BG107173A patent/BG107173A/bg unknown
- 2002-10-10 IL IL152248A patent/IL152248A/en not_active IP Right Cessation
- 2002-10-11 NO NO20024908A patent/NO325337B1/no unknown
- 2002-10-11 NO NO20024907A patent/NO20024907L/no not_active Application Discontinuation
- 2002-11-11 HR HR20020892A patent/HRP20020892B1/xx not_active IP Right Cessation
2004
- 2004-01-09 HK HK04100140.5A patent/HK1057219A1/xx not_active IP Right Cessation
2008
- 2008-03-11 US US12/045,979 patent/US20080182829A1/en not_active Abandoned
- 2008-06-25 JP JP2008166585A patent/JP2008280355A/ja active Pending

Also Published As

Publication number	Publication date
EA200201052A1 (ru)	2003-04-24
CN100453549C (zh)	2009-01-21
HRP20020892A2 (en)	2005-02-28
JP3828423B2 (ja)	2006-10-04
DK1272505T3 (da)	2005-11-07
MXPA02010066A (es)	2003-06-04
US7378404B2 (en)	2008-05-27
NO20024907D0 (no)	2002-10-11
ATE363487T1 (de)	2007-06-15
US20040029847A1 (en)	2004-02-12
WO2001077138A1 (de)	2001-10-18
DK1272504T3 (da)	2007-10-01
CA2406177C (en)	2010-06-22
EP1272504A1 (de)	2003-01-08
JP2008280355A (ja)	2008-11-20
EA006299B1 (ru)	2005-10-27
AU2001258341B2 (en)	2007-03-15
JP2003530403A (ja)	2003-10-14
CA2406177A1 (en)	2001-10-18
WO2001077139A1 (de)	2001-10-18
PT1272504E (pt)	2007-08-29
AU2001273945A1 (en)	2001-10-23
ES2245694T3 (es)	2006-01-16
PL207488B1 (pl)	2010-12-31
SK14632002A3 (sk)	2003-03-04
DE50112561D1 (de)	2007-07-12
US20080182829A1 (en)	2008-07-31
ATE302790T1 (de)	2005-09-15
IL152248A0 (en)	2003-05-29
HUP0300335A2 (hu)	2003-07-28
EP1272504B1 (de)	2007-05-30
NO325337B1 (no)	2008-03-31
NZ543724A (en)	2007-07-27
PL358667A1 (en)	2004-08-09
ES2287127T3 (es)	2007-12-16
EE200200589A (et)	2004-04-15
BG107173A (bg)	2003-05-30
CZ20023382A3 (cs)	2003-02-12
AU5834101A (en)	2001-10-23
NO20024908D0 (no)	2002-10-11
BR0109983A (pt)	2003-02-25
IL152248A (en)	2008-06-05
NO20024907L (no)	2002-12-05
EP1272505B1 (de)	2005-08-24
US20030176405A1 (en)	2003-09-18
EP1272505A1 (de)	2003-01-08
HRP20020892B1 (en)	2011-08-31
CN1433424A (zh)	2003-07-30
HK1057219A1 (en)	2004-03-19

Publication	Publication Date	Title
NO20024908L (no)	2002-11-13	8<beta>-hydrokarbyl-substituerte östratriener for anvendelse som selektive östrogener
RU97104120A (ru)	1999-04-20	Фармацевтические композиции, содержащие производные эстра-1,3,5(10)-триена
EA200100108A1 (ru)	2001-12-24	Применение биогенных сульфаматов эстрогенов для гормонзаместительной терапии
ES2299730T3 (es)	2008-06-01	Composicion farmaceutica que comprende derivados de estetrol para el uso en la terapia del cancer.
ECSP055530A (es)	2005-03-10	Estratrienos 9-alfa-sustituidos como estrógenos de eficacia selectiva
YU57201A (sh)	2005-06-10	16-hidroksiestratrieni kao selektivno aktivni estrogeni
ES2286042T3 (es)	2007-12-01	18-nor-esteroides como estrogenos eficaces selectivamente.
ES2300431T3 (es)	2008-06-16	Esteroides androgenos halogenados en posicion 11 y sustituidos en posicion 7.
TN2010000007A1 (en)	2011-09-26	8-beta- substituted estratrienes as selectively active estrogens
UY26665A1 (es)	2001-11-30	Estratrienos sustituidos como estrógenos selectivamente activos
ES2260294T3 (es)	2006-11-01	17-metilen-esteroides halogenados en posicion 4, procedimientos para su preparacion y composiciones que contienen estos compuestos.
UY26967A1 (es)	2003-04-30	Derivados 8beta-sustituidos de 11beta-pentil y 11beta-hexil-estra-1,3,5(10)-trieno.-
KR20080072087A (ko)	2008-08-05	Ｅｒ-베타 선택적 물질의 전구약물, 그의 제조 방법 및그것을 포함하는 제약 조성물
RU2006126632A (ru)	2008-01-27	Стероиды, имеющие смешанный андрогенный и прогрестагенный профиль